Aqtual

Executive Summary

Aqtual, a San Francisco-based diagnostics company founded in 2020, is pioneering a novel approach to chronic disease and oncology management through its advanced liquid biopsy platform. By analyzing cell-free DNA from a single blood draw, the company derives epigenetics, gene regulation, and transcriptomic insights, enabling highly accurate disease detection, monitoring, and patient stratification. Its technology aims to bridge the gap between research and clinical practice, offering a non-invasive solution that could transform how diseases are tracked and treated over time. Despite being in an early stage with limited public financing details, Aqtual's focus on multi-omic analysis from a simple blood test positions it strongly in the rapidly growing liquid biopsy market, which is projected to exceed $6 billion by 2030. The company's platform holds promise for both oncology and chronic conditions such as diabetes and cardiovascular diseases, where early detection and longitudinal monitoring are critical. Aqtual's ability to integrate multiple layers of molecular information from a single sample could differentiate it from competitors that target only one modality. However, as a private startup with no disclosed funding or revenue, the company faces significant development and regulatory hurdles. Near-term success will depend on securing capital to advance its technology through clinical validation. If successful, Aqtual's tests could offer a cost-effective and scalable solution for precision medicine, potentially reducing healthcare costs and improving patient outcomes.

Upcoming Catalysts (preview)

• TBDSeries A Funding Round Announcement60% success
• Q4 2026Initial Clinical Data from Liquid Biopsy Study in Oncology50% success
• Q2 2026Partnership with Academic Medical Center for Chronic Disease Monitoring70% success